Form 4: Director Nancy Lurker Sells 4,500 Shares of Collegium

Director Nancy Lurker sold 4,500 shares of Collegium Pharmaceutical, Inc. common stock at a weighted average price of $35.9691.

Summary

• Director Nancy Lurker executed a sale of 4,500 shares of Collegium Pharmaceutical, Inc. (COLL) common stock.
• The transaction occurred on May 13, 2026.
• The shares were sold at a weighted average price of $35.9691, with individual trade prices ranging from $35.55 to $36.50.
• Following this transaction, Nancy Lurker retains beneficial ownership of 18,017 shares of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine disclosure of an insider transaction that does not signal a fundamental shift in company operations.

Positives

• The transaction represents a standard divestment by a director rather than a company-wide financial event.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term share price appreciation.

Risks

• Market volatility affecting the share price of pharmaceutical equities.
• Regulatory and clinical risks inherent to the pharmaceutical industry.

Future Outlook

The filing does not provide forward-looking guidance or strategic outlooks, as it is a mandatory disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that director sales are common in the pharmaceutical sector for liquidity or portfolio rebalancing purposes and do not necessarily reflect a change in the company's fundamental business trajectory.

Comparison to Industry Standards

• Insider selling activity is a routine occurrence among mid-cap pharmaceutical companies.
• The volume of shares sold (4,500) is relatively small compared to the total outstanding shares of Collegium Pharmaceutical.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale represents a small portion of the director's holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Collegium Pharmaceutical, COLL, Insider Trading, Form 4, Nancy Lurker, Director Sale